XML 45 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders’ Equity and Stock-Based Compensation (Tables)
12 Months Ended
Dec. 25, 2021
Equity [Abstract]  
Schedule of Non-vested Restricted Stock Activity

 

   Shares   Weighted Average Grant Fair Value 
Balance at December 28, 2019   1,863,124   $1.60 
Granted   2,381,000    1.42 
Forfeited   (153,595)   1.71 
Vested   (1,038,655)   0.96 
Balance at December 26, 2020   3,051,874    1.67 
Granted   2,247,343    3.46 
Forfeited   (1,654,666)   2.03 
Vested   (1,566,959)   2.23 
Balance at December 25, 2021   2,077,592   $2.90 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions

 

Expected volatility   94.2%
Interest rate   0.2%
Expected life (years)   0.7 
Dividend yield   %
Schedule of Stock-based Compensation Expense

The following table summarizes stock-based compensation expense within each of the categories below as it relates to non-vested restricted common stock awards for the fiscal years 2021, 2020 and 2019 (no tax benefits were recognized):

 

 

   2021   2020   2019 
Cost of product revenues  $211,362   $113,517   $102,629 
Research and development   576,193    204,599    295,872 
Selling, general and administrative   3,629,867    503,006    1,658,899 
Total  $4,417,422   $821,122   $2,057,400